EA038665B1 - Модуляторы фарнезоидного x-рецептора - Google Patents

Модуляторы фарнезоидного x-рецептора Download PDF

Info

Publication number
EA038665B1
EA038665B1 EA201890899A EA201890899A EA038665B1 EA 038665 B1 EA038665 B1 EA 038665B1 EA 201890899 A EA201890899 A EA 201890899A EA 201890899 A EA201890899 A EA 201890899A EA 038665 B1 EA038665 B1 EA 038665B1
Authority
EA
Eurasian Patent Office
Prior art keywords
compound
disease
present
mmol
liver
Prior art date
Application number
EA201890899A
Other languages
English (en)
Russian (ru)
Other versions
EA201890899A1 (ru
Inventor
Роберто Пелличари
Антимо Джойелло
Original Assignee
Интерсепт Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Интерсепт Фармасьютикалз, Инк. filed Critical Интерсепт Фармасьютикалз, Инк.
Publication of EA201890899A1 publication Critical patent/EA201890899A1/ru
Publication of EA038665B1 publication Critical patent/EA038665B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/001Oxiranes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
EA201890899A 2015-10-07 2016-10-07 Модуляторы фарнезоидного x-рецептора EA038665B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562238246P 2015-10-07 2015-10-07
PCT/US2016/055980 WO2017062763A1 (en) 2015-10-07 2016-10-07 Farnesoid x receptor modulators

Publications (2)

Publication Number Publication Date
EA201890899A1 EA201890899A1 (ru) 2018-09-28
EA038665B1 true EA038665B1 (ru) 2021-09-30

Family

ID=58488545

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890899A EA038665B1 (ru) 2015-10-07 2016-10-07 Модуляторы фарнезоидного x-рецептора

Country Status (26)

Country Link
US (3) US11034717B2 (enExample)
EP (2) EP3359160B1 (enExample)
JP (2) JP7021080B2 (enExample)
KR (2) KR20180061351A (enExample)
CN (1) CN108348530B (enExample)
AR (1) AR106293A1 (enExample)
AU (1) AU2016335765B2 (enExample)
BR (1) BR112018006892B1 (enExample)
CA (1) CA3000881C (enExample)
CL (1) CL2018000883A1 (enExample)
CO (1) CO2018003728A2 (enExample)
CR (1) CR20180201A (enExample)
DK (1) DK3359160T3 (enExample)
EA (1) EA038665B1 (enExample)
EC (1) ECSP18030284A (enExample)
ES (1) ES2898705T3 (enExample)
IL (1) IL258359B2 (enExample)
MA (2) MA42339A1 (enExample)
MX (1) MX387172B (enExample)
PH (1) PH12018500777A1 (enExample)
SV (1) SV2018005662A (enExample)
TN (1) TN2018000106A1 (enExample)
TW (1) TW201718621A (enExample)
UA (1) UA123948C2 (enExample)
WO (1) WO2017062763A1 (enExample)
ZA (1) ZA201802901B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170094184A (ko) 2014-11-06 2017-08-17 이난타 파마슈티칼스, 인코포레이티드 Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
KR20170099909A (ko) 2014-11-26 2017-09-01 이난타 파마슈티칼스, 인코포레이티드 Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법
WO2016086115A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
SG11201706089RA (en) 2015-02-11 2017-09-28 Enanta Pharm Inc Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
PT3277286T (pt) 2015-03-31 2021-07-01 Enanta Pharm Inc Derivados de ácidos biliares como agonistas de fxr/tgr5 e métodos de utilização destes
EP3359160B1 (en) 2015-10-07 2021-08-25 Intercept Pharmaceuticals, Inc. Farnesoid x receptor modulators
WO2017147174A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
US10364267B2 (en) 2016-02-23 2019-07-30 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
WO2017147137A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
WO2018102418A1 (en) 2016-11-29 2018-06-07 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonylurea bile acid derivatives
US10472386B2 (en) 2017-02-14 2019-11-12 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR agonists and methods of use thereof
WO2018187804A1 (en) 2017-04-07 2018-10-11 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonyl carbamate bile acid derivatives
KR20250109791A (ko) 2017-06-23 2025-07-17 인터셉트 파마슈티컬즈, 인크. 담즙산 유도체 제조를 위한 방법 및 중간체
CN111050772A (zh) 2017-07-24 2020-04-21 英特塞普特医药品公司 同位素标记的胆汁酸衍生物
ES2999311T3 (en) * 2017-12-19 2025-02-25 Xian Biocare Pharma Ltd Compound for treating metabolic diseases and preparation method and use thereof
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
WO2020243590A1 (en) 2019-05-30 2020-12-03 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
WO2023288123A1 (en) 2021-07-16 2023-01-19 Interecept Pharmaceuticals, Inc. Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100093687A1 (en) * 2001-05-03 2010-04-15 University Of Chicago Method Of Treating Disorder Related To High Cholesterol Concentration
US20120283234A1 (en) * 2006-06-27 2012-11-08 Intercept Pharmaceuticals, Inc. Bile Acid Derivatives As FXR Ligands For The Prevention Or Treatment Of FXR-Mediated Diseases Or Conditions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2599481A (en) 1948-09-28 1952-06-03 Ciba Pharm Prod Inc Reduction of steroid epoxides
EP0101554B1 (en) * 1982-07-29 1986-10-15 Lehner A.G. New derivatives of biliary acids, process for the production thereof and pharmaceutical compositions containing the same
IT1223313B (it) 1987-10-20 1990-09-19 Gipharmex Spa Derivati di acidi biliari loro preparazione e composizioni farmaceutiche che li contengono
DE10113257C1 (de) 2001-03-19 2002-11-14 Inst Mikrotechnik Mainz Gmbh Elektrophoresevorrichtung und ihre Verwendung
DK2376519T3 (da) * 2008-11-19 2014-02-03 Intercept Pharmaceuticals Inc TGR5-modulatorer og fremgangsmåde til anvendelse deraf
EA201990211A1 (ru) 2012-06-19 2019-06-28 Интерсепт Фармасьютикалз, Инк. Получение, применение и твердые формы обетихолевой кислоты
KR102106186B1 (ko) * 2012-11-28 2020-05-04 인터셉트 파마슈티컬즈, 인크. 폐 질환의 치료
ES2847002T3 (es) 2013-05-14 2021-07-30 Intercept Pharmaceuticals Inc Derivados 11-hidroxil-6-sustituidos de ácidos biliares y conjugados de aminoácido de los mismos como moduladores del receptor X farnesoide
US9351083B2 (en) 2013-10-17 2016-05-24 Turtle Beach Corporation Transparent parametric emitter
KR20170099909A (ko) * 2014-11-26 2017-09-01 이난타 파마슈티칼스, 인코포레이티드 Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법
WO2016086115A1 (en) * 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
EP3359160B1 (en) 2015-10-07 2021-08-25 Intercept Pharmaceuticals, Inc. Farnesoid x receptor modulators
MX2018003914A (es) 2015-10-07 2018-05-23 Stoller Ets Manejo de etileno en plantas mediante el uso de una formula agricola sinergica que comprende diacil o diarilurea y al menos un complejo de metales.
SG11201807784SA (en) 2016-03-11 2018-10-30 Intercept Pharmaceuticals Inc 3-desoxy derivative and pharmaceutical compositions thereof
KR20250109791A (ko) * 2017-06-23 2025-07-17 인터셉트 파마슈티컬즈, 인크. 담즙산 유도체 제조를 위한 방법 및 중간체
WO2020243590A1 (en) 2019-05-30 2020-12-03 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100093687A1 (en) * 2001-05-03 2010-04-15 University Of Chicago Method Of Treating Disorder Related To High Cholesterol Concentration
US20120283234A1 (en) * 2006-06-27 2012-11-08 Intercept Pharmaceuticals, Inc. Bile Acid Derivatives As FXR Ligands For The Prevention Or Treatment Of FXR-Mediated Diseases Or Conditions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PUBCHEM, Substance Record for SID 236277322 Create Date: 2015-02-15 [retrieved on 15 November 2016]; Retrieved from the Internet: https://pubchem.ncbi.nlm.nih.gov/substance/236277322 entire document *
PUBCHEM, Substance Record for SID 85207872 Create Date: 2009-09-28 [retrieved on 15 November 2016]; Retrieved from the Internet: https://pubchem.ncbi.nlm.nih.gov/substance/85207872 entire document *
VANDENHEUVEL. Gas-liquid chromatographic studies of reactions and structural relationships of steroids: II. Positions 3, 11 and 20 in the pregnane series. Journal of Chromatography A, 103 (1), 113-134, 1975 [retrieved on 27 January 2017]; Retrieved from the Internet. <http://www.sciencedirect com/science/article/pii/S0021967300838066> entire document *

Also Published As

Publication number Publication date
MX2018004186A (es) 2018-05-17
AU2016335765A1 (en) 2018-04-19
CA3000881A1 (en) 2017-04-13
US20170101434A1 (en) 2017-04-13
JP2019210297A (ja) 2019-12-12
EP3359160A4 (en) 2019-06-05
JP2018530559A (ja) 2018-10-18
IL258359B2 (en) 2023-11-01
KR20180061351A (ko) 2018-06-07
CN108348530A (zh) 2018-07-31
EP3359160B1 (en) 2021-08-25
CA3000881C (en) 2024-03-19
SV2018005662A (es) 2018-12-14
TN2018000106A1 (en) 2019-10-04
TW201718621A (zh) 2017-06-01
US20250376488A1 (en) 2025-12-11
EP3981779A1 (en) 2022-04-13
KR20250120445A (ko) 2025-08-08
BR112018006892B1 (pt) 2023-04-11
PH12018500777A1 (en) 2018-10-29
MA42339A1 (fr) 2019-01-31
AR106293A1 (es) 2018-01-03
US11034717B2 (en) 2021-06-15
CO2018003728A2 (es) 2018-07-31
CN108348530B (zh) 2023-09-29
EA201890899A1 (ru) 2018-09-28
BR112018006892A2 (pt) 2018-10-16
EP3359160A1 (en) 2018-08-15
ZA201802901B (en) 2019-07-31
ES2898705T3 (es) 2022-03-08
CL2018000883A1 (es) 2018-06-29
IL258359A (en) 2018-06-28
AU2016335765B2 (en) 2022-01-06
US20210269475A1 (en) 2021-09-02
ECSP18030284A (es) 2018-05-31
MA45761A (fr) 2021-04-21
CR20180201A (es) 2018-08-24
MX387172B (es) 2025-03-19
WO2017062763A1 (en) 2017-04-13
US12291549B2 (en) 2025-05-06
DK3359160T3 (da) 2021-11-22
UA123948C2 (uk) 2021-06-30
JP7021080B2 (ja) 2022-02-16
NZ741058A (en) 2024-05-31
IL258359B1 (en) 2023-07-01
HK1253558A1 (zh) 2019-06-21

Similar Documents

Publication Publication Date Title
US12291549B2 (en) Farnesoid X receptor modulators
US11319337B2 (en) 3-desoxy derivative and pharmaceutical compositions thereof
ES2936638T3 (es) Derivados sustituidos con 11-Hidroxil-6 de ácidos biliares y conjugados de aminoácidos de los mismos como moduladores del receptor X farnesoide
HK1253558B (zh) 法尼醇x受体调节剂
HK1259145B (zh) 3-脱氧衍生物及其药物组合物